Related Experiment Videos
[Thrombolysis in acute myocardial infarct: a status determination 1988]
1Abteilung für Kardiologie und Pulmologie, Freien Universität Berlin.
Insights
Intravenous thrombolysis within 6 hours of myocardial infarction symptoms improves survival. Further trials are needed to compare thrombolytic agents, focusing on mortality reduction and infarct size limitation.
Area of Science:
- Cardiology
- Emergency Medicine
- Pharmacology
Background:
- Myocardial infarction (MI) remains a leading cause of mortality worldwide.
- Timely reperfusion therapy is critical for improving outcomes in acute MI.
- Intravenous thrombolysis has been a cornerstone of MI treatment, but its optimal use and comparison with other strategies require ongoing evaluation.
Purpose of the Study:
- To review the current literature on intravenous thrombolysis for acute myocardial infarction.
- To assess the efficacy and safety of thrombolytic agents.
- To provide evidence-based recommendations for clinical practice regarding thrombolytic therapy and revascularization strategies.
Main Methods:
- Systematic review of pertinent literature from the last decade.
- Analysis of randomized controlled trials comparing thrombolytic agents.
- Evaluation of outcomes including survival, infarct size, left ventricular function, and adverse events.
Main Results:
- Intravenous thrombolysis within 6 hours of MI symptom onset significantly improves survival.
- Efficacy should be measured by mortality reduction and infarct size limitation, not just coronary patency.
- Early treatment (within 4 hours) is crucial for direct salvage of ischemic myocardium.
- Immediate invasive strategies (angiography, angioplasty) are not superior and carry higher risks.
- Hemorrhagic events are the main side effect, but intracranial hemorrhage risk is balanced by reduced ischemic strokes with acetylsalicylic acid.
Conclusions:
- Intravenous thrombolysis is effective in improving survival after myocardial infarction.
- Further randomized trials are needed to compare different thrombolytic agents.
- Minimizing invasive procedures is important due to bleeding risks.
- Patients with persistent ischemia post-MI require further evaluation for revascularization.
Abstract:
This article reviews the pertinent literature from the last decade. The following conclusions are drawn: 1) Intravenous thrombolysis given within 6 h after onset of myocardial infarction symptoms significantly improves short- and long-term survival. To evaluate the relative efficacy and safety of various thrombolytic agents, randomized trials directly comparing these agents are needed. 2) Efficacy of thrombolysis must be demonstrated not just by restoring coronary patency, but in consistent limitation of infarct size and more so in reduced short- and long-term mortality. 3) Long-term improvement of left ventricular function due to adequate reperfusion of an infarct-related artery most probably is the essential mechanism for reduced mortality. For direct salvage of ischemic myocardium, however, initiation of treatment within 4 h of symptom onset is mandatory. 4) Immediate coronary angiography and angioplasty is not superior to non-invasive treatment but carries a significant complication and mortality risk. Thus, immediate invasive strategy should be avoided. 5) The major untoward side effects related to thrombolysis are hemorrhagic events predominantly at catheterization or other puncture sites; this stresses the need for minimizing invasive procedures. A more frequent occurrence of intracranial hemorrhage is balanced by less ischemic strokes, especially with additional administration of acetylsalicyclic acid. 6) Thrombolytic therapy carries the risk of continuing ischemia post infarction. Patients with persistent or recurrent clinical symptoms or a major ischemic response detected by non-invasive risk stratification need coronary angiography and revascularization therapy. The role of revascularization therapy in patients with minor or no ischemic response to early submaximal exercise testing requires further studies.